| Name | Title | Contact Details |
|---|---|---|
Jaci Leitheiser |
Chief Counsel | Profile |
Andwin Scientific specializes in product distribution both as a distributor to direct end using companies, and as a supplier/vendor to national and international supply houses. This effort is supported by offices in North Carolina and Illinois
We believe everyone deserves affordable and convenient healthcare. Our mission is to build better ways for people to find the right care at the best price. Our technology gives all Americans — regardless of income or insurance status — the knowledge, choice, and care they need to stay healthy. GoodRx supports all Americans with their healthcare challenges. Since 2011, we`ve helped Americans save over $35 billion on prescriptions via savings cards, our website, and the GoodRx app, which is one of the most downloaded medical apps on both the Google Play and Apple App Store. We`re a customer-first company. That means making sure all our products and features are built around you. This approach guides how we operate, make decisions across our businesses, and work on new ideas for our customers. In 2021, an estimated 46 million U.S. adults were not able to afford needed care. We`re working to narrow this access gap. We have saved Americans over $30 billion on their medications.
Integrated Recovery Products is a Costa Mesa, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Heal brings a licensed, background-checked pediatrician or family doctor to you, on-demand, on your schedule, for $99 or in-network with your insurance. Great doctors are available in Los Angeles, Orange County, Silicon Valley, San Diego and San Francisco from 8am to 8pm, seven days a week.
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.